Now showing items 1-20 of 23

    • A streamlined workflow for single-cells genome-wide copy-number profiling by low-pass sequencing of LM-PCR whole-genome amplification products. 

      Ferrarini, A; Forcato, C; Buson, G; Tononi, P; Del Monaco, V; Terracciano, M; Bolognesi, C; Fontana, F; Medoro, G; Neves, R; Möhlendick, B; Rihawi, K; Ardizzoni, A; Sumanasuriya, S; Flohr, P; Lambros, M; de Bono, J; Stoecklein, NH; Manaresi, N (2018-01)
      Chromosomal instability and associated chromosomal aberrations are hallmarks of cancer and play a critical role in disease progression and development of resistance to drugs. Single-cell genome analysis has gained interest ...
    • Application of Liquid Biopsies in Cancer Targeted Therapy. 

      Sumanasuriya, S; Lambros, MB; de Bono, JS (2017-11)
      As a growing body of evidence demonstrates intertumoral and intratumoral heterogeneity and clonal evolution, both during carcinogenesis and also throughout treatment resulting in acquired drug resistance, the utility of ...
    • Applications of liquid biopsies in metastatic castration resistant prostate cancer 

      Sumanasuriya, S (2020-02-29)
      Despite many recent advances, treating advanced prostate cancer (PC) remains clinically challenging. The need for vaildated circulating biomarkers is well recognised in almost all cancers, including in PC. Whilst circulating ...
    • BRD4 Promotes DNA Repair and Mediates the Formation of TMPRSS2-ERG Gene Rearrangements in Prostate Cancer. 

      Li, X; Baek, G; Ramanand, SG; Sharp, A; Gao, Y; Yuan, W; Welti, J; Rodrigues, DN; Dolling, D; Figueiredo, I; Sumanasuriya, S; Crespo, M; Aslam, A; Li, R; Yin, Y; Mukherjee, B; Kanchwala, M; Hughes, AM; Halsey, WS; Chiang, C-M; Xing, C; Raj, GV; Burma, S; de Bono, J; Mani, RS (2018-01)
      BRD4 belongs to the bromodomain and extraterminal (BET) family of chromatin reader proteins that bind acetylated histones and regulate gene expression. Pharmacological inhibition of BRD4 by BET inhibitors (BETi) has indicated ...
    • Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition. 

      Goodall, J; Mateo, J; Yuan, W; Mossop, H; Porta, N; Miranda, S; Perez-Lopez, R; Dolling, D; Robinson, DR; Sandhu, S; Fowler, G; Ebbs, B; Flohr, P; Seed, G; Rodrigues, DN; Boysen, G; Bertan, C; Atkin, M; Clarke, M; Crespo, M; Figueiredo, I; Riisnaes, R; Sumanasuriya, S; Rescigno, P; Zafeiriou, Z; Sharp, A; Tunariu, N; Bianchini, D; Gillman, A; Lord, CJ; Hall, E; Chinnaiyan, AM; Carreira, S; de Bono, JS; TOPARP-A investigators (2017-09)
      Biomarkers for more precise patient care are needed in metastatic prostate cancer. We have reported a phase II trial (TOPARP-A) of the PARP inhibitor olaparib in metastatic prostate cancer, demonstrating antitumor activity ...
    • Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer. 

      Sharp, A; Welti, JC; Lambros, MBK; Dolling, D; Rodrigues, DN; Pope, L; Aversa, C; Figueiredo, I; Fraser, J; Ahmad, Z; Lu, C; Rescigno, P; Kolinsky, M; Bertan, C; Seed, G; Riisnaes, R; Miranda, S; Crespo, M; Pereira, R; Ferreira, A; Fowler, G; Ebbs, B; Flohr, P; Neeb, A; Bianchini, D; Petremolo, A; Sumanasuriya, S; Paschalis, A; Mateo, J; Tunariu, N; Yuan, W; Carreira, S; Plymate, SR; Luo, J; de Bono, JS (2019-11)
      Background Detection of androgen receptor splice variant-7 (AR-V7) mRNA in circulating tumour cells (CTCs) is associated with worse outcome in metastatic castration-resistant prostate cancer (mCRPC). However, studies rarely ...
    • Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer. 

      Sumanasuriya, S; Omlin, A; Armstrong, A; Attard, G; Chi, KN; Bevan, CL; Shibakawa, A; IJzerman, MJ; De Laere, B; Lolkema, M; Lorente, D; Luo, J; Mehra, N; Olmos, D; Scher, H; Soule, H; Stoecklein, NH; Terstappen, LWMM; Waugh, D; de Bono, JS (2018-06)
      Context In advanced prostate cancer (PC), there is increasing investigation of circulating biomarkers, including quantitation and characterization of circulating tumour cells and cell-free nucleic acids, for therapeutic ...
    • Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers. 

      Rescigno, P; Lorente, D; Dolling, D; Ferraldeschi, R; Rodrigues, DN; Riisnaes, R; Miranda, S; Bianchini, D; Zafeiriou, Z; Sideris, S; Ferreira, A; Figueiredo, I; Sumanasuriya, S; Mateo, J; Perez-Lopez, R; Sharp, A; Tunariu, N; de Bono, JS (2018-05)
      Background Loss of PTEN is a common genomic aberration in castration-resistant prostate cancer (CRPC) and is frequently concurrent with ERG rearrangements, causing resistance to next-generation hormonal treatment (NGHT) ...
    • Effect on Overall Survival of Locoregional Treatment in a Cohort of De Novo Metastatic Prostate Cancer Patients: A Single Institution Retrospective Analysis From the Royal Marsden Hospital. 

      Bianchini, D; Lorente, D; Rescigno, P; Zafeiriou, Z; Psychopaida, E; O'Sullivan, H; Alaras, M; Kolinsky, M; Sumanasuriya, S; Sousa Fontes, M; Mateo, J; Perez Lopez, R; Tunariu, N; Fotiadis, N; Kumar, P; Tree, A; Van As, N; Khoo, V; Parker, C; Eeles, R; Thompson, A; Dearnaley, D; de Bono, JS (2017-10)
      Background The optimal management of the primary tumor in metastatic at diagnosis (M1) prostate cancer (PCa) patients is not yet established. We retrospectively evaluated the effect of locoregional treatment (LRT) on overall ...
    • Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency. 

      Zafeiriou, Z; Bianchini, D; Chandler, R; Rescigno, P; Yuan, W; Carreira, S; Barrero, M; Petremolo, A; Miranda, S; Riisnaes, R; Rodrigues, DN; Gurel, B; Sumanasuriya, S; Paschalis, A; Sharp, A; Mateo, J; Tunariu, N; Chinnaiyan, AM; Pritchard, CC; Kelly, K; de Bono, JS (2019-01)
      Platinum-based regimens have not been proved to increase survival from advanced prostate cancer (PCa). Incontrovertible evidence that a proportion of prostate cancers have homologous recombination DNA (HRD) repair defects, ...
    • Genomics of lethal prostate cancer at diagnosis and castration resistance. 

      Mateo, J; Seed, G; Bertan, C; Rescigno, P; Dolling, D; Figueiredo, I; Miranda, S; Nava Rodrigues, D; Gurel, B; Clarke, M; Atkin, M; Chandler, R; Messina, C; Sumanasuriya, S; Bianchini, D; Barrero, M; Petermolo, A; Zafeiriou, Z; Fontes, M; Perez-Lopez, R; Tunariu, N; Fulton, B; Jones, R; McGovern, U; Ralph, C; Varughese, M; Parikh, O; Jain, S; Elliott, T; Sandhu, S; Porta, N; Hall, E; Yuan, W; Carreira, S; de Bono, JS (2020-04)
      The genomics of primary prostate cancer differ from those of metastatic castration-resistant prostate cancer (mCRPC). We studied genomic aberrations in primary prostate cancer biopsies from patients who developed mCRPC, ...
    • IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. 

      Calcinotto, A; Spataro, C; Zagato, E; Di Mitri, D; Gil, V; Crespo, M; De Bernardis, G; Losa, M; Mirenda, M; Pasquini, E; Rinaldi, A; Sumanasuriya, S; Lambros, MB; Neeb, A; Lucianò, R; Bravi, CA; Nava-Rodrigues, D; Dolling, D; Prayer-Galetti, T; Ferreira, A; Briganti, A; Esposito, A; Barry, S; Yuan, W; Sharp, A; de Bono, J; Alimonti, A (2018-07)
      Patients with prostate cancer frequently show resistance to androgen-deprivation therapy, a condition known as castration-resistant prostate cancer (CRPC). Acquiring a better understanding of the mechanisms that control ...
    • Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. 

      Nava Rodrigues, D; Rescigno, P; Liu, D; Yuan, W; Carreira, S; Lambros, MB; Seed, G; Mateo, J; Riisnaes, R; Mullane, S; Margolis, C; Miao, D; Miranda, S; Dolling, D; Clarke, M; Bertan, C; Crespo, M; Boysen, G; Ferreira, A; Sharp, A; Figueiredo, I; Keliher, D; Aldubayan, S; Burke, KP; Sumanasuriya, S; Fontes, MS; Bianchini, D; Zafeiriou, Z; Teixeira Mendes, LS; Mouw, K; Schweizer, MT; Pritchard, CC; Salipante, S; Taplin, M-E; Beltran, H; Rubin, MA; Cieslik, M; Robinson, D; Heath, E; Schultz, N; Armenia, J; Abida, W; Scher, H; Lord, C; D'Andrea, A; Sawyers, CL; Chinnaiyan, AM; Alimonti, A; Nelson, PS; Drake, CG; Van Allen, EM; de Bono, JS (2018-10)
      Background Understanding the integrated immunogenomic landscape of advanced prostate cancer (APC) could impact stratified treatment selection.Methods Defective mismatch repair (dMMR) status was determined by either loss ...
    • Neutrophil to Lymphocyte Ratio in Castration-Resistant Prostate Cancer Patients Treated With Daily Oral Corticosteroids. 

      Mehra, N; Sharp, A; Lorente, D; Dolling, D; Sumanasuriya, S; Johnson, B; Dearnaley, D; Parker, C; de Bono, J (2017-12)
      Background The neutrophil to lymphocyte ratio (NLR) has been shown to be highly prognostic across many tumor types, and predictive of treatment outcome in advanced prostate cancer, and has been postulated to be an indirect ...
    • Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA). 

      Mehra, N; Dolling, D; Sumanasuriya, S; Christova, R; Pope, L; Carreira, S; Seed, G; Yuan, W; Goodall, J; Hall, E; Flohr, P; Boysen, G; Bianchini, D; Sartor, O; Eisenberger, MA; Fizazi, K; Oudard, S; Chadjaa, M; Macé, S; de Bono, JS (2018-09)
      BACKGROUND:Noninvasive biomarkers are needed to guide metastatic castration-resistant prostate cancer (mCRPC) treatment. OBJECTIVE:To clinically qualify baseline and on-treatment cell-free DNA (cfDNA) concentrations as ...
    • Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. 

      Rescigno, P; Lorente, D; Bianchini, D; Ferraldeschi, R; Kolinsky, MP; Sideris, S; Zafeiriou, Z; Sumanasuriya, S; Smith, AD; Mehra, N; Jayaram, A; Perez-Lopez, R; Mateo, J; Parker, C; Dearnaley, DP; Tunariu, N; Reid, A; Attard, G; de Bono, JS (2016-11)
      Background The availability of multiple new treatments for metastatic castration-resistant prostate cancer (mCRPC) mandates earlier treatment switches in the absence of a response. A decline in prostate-specific antigen ...
    • Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer. 

      Paschalis, A; Sheehan, B; Riisnaes, R; Rodrigues, DN; Gurel, B; Bertan, C; Ferreira, A; Lambros, MBK; Seed, G; Yuan, W; Dolling, D; Welti, JC; Neeb, A; Sumanasuriya, S; Rescigno, P; Bianchini, D; Tunariu, N; Carreira, S; Sharp, A; Oyen, W; de Bono, JS (2019-10)
      <h4>Background</h4>Prostate-specific membrane antigen (PSMA; folate hydrolase) prostate cancer (PC) expression has theranostic utility.<h4>Objective</h4>To elucidate PC PSMA expression and associate this with defective DNA ...
    • RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer. 

      Nava Rodrigues, D; Casiraghi, N; Romanel, A; Crespo, M; Miranda, S; Rescigno, P; Figueiredo, I; Riisnaes, R; Carreira, S; Sumanasuriya, S; Gasperini, P; Sharp, A; Mateo, J; Makay, A; McNair, C; Schiewer, M; Knudsen, K; Boysen, G; Demichelis, F; de Bono, JS (2019-01)
      Purpose Metastatic castration-resistant prostate cancer (mCRPC) is a lethal but clinically heterogeneous disease, with patients having variable benefit from endocrine and cytotoxic treatments. Intrapatient genomic heterogeneity ...
    • Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis. 

      Lambros, MB; Seed, G; Sumanasuriya, S; Gil, V; Crespo, M; Fontes, M; Chandler, R; Mehra, N; Fowler, G; Ebbs, B; Flohr, P; Miranda, S; Yuan, W; Mackay, A; Ferreira, A; Pereira, R; Bertan, C; Figueiredo, I; Riisnaes, R; Rodrigues, DN; Sharp, A; Goodall, J; Boysen, G; Carreira, S; Bianchini, D; Rescigno, P; Zafeiriou, Z; Hunt, J; Moloney, D; Hamilton, L; Neves, RP; Swennenhuis, J; Andree, K; Stoecklein, NH; Terstappen, LWMM; de Bono, JS (2018-11)
      <b>Purpose:</b> Circulating tumor cells (CTCs) have clinical relevance, but their study has been limited by their low frequency.<b>Experimental Design:</b> We evaluated liquid biopsies by apheresis to increase CTC yield ...
    • SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity. 

      Boysen, G; Rodrigues, DN; Rescigno, P; Seed, G; Dolling, D; Riisnaes, R; Crespo, M; Zafeiriou, Z; Sumanasuriya, S; Bianchini, D; Hunt, J; Moloney, D; Perez-Lopez, R; Tunariu, N; Miranda, S; Figueiredo, I; Ferreira, A; Christova, R; Gil, V; Aziz, S; Bertan, C; de Oliveira, FM; Atkin, M; Clarke, M; Goodall, J; Sharp, A; MacDonald, T; Rubin, MA; Yuan, W; Barbieri, CE; Carreira, S; Mateo, J; de Bono, JS (2018-11)
      <b>Purpose:</b> <i>CHD1</i> deletions and <i>SPOP</i> mutations frequently cooccur in prostate cancer with lower frequencies reported in castration-resistant prostate cancer (CRPC). We monitored CHD1 expression during ...